Search Results

search

Search Filters

Organization
Boehringer Ingelheim Limited
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
July 29, 2024 02:05 ET | Boehringer Ingelheim
The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction...
Boehringer_Workplace_Lab_Research
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
July 18, 2024 03:05 ET | Boehringer Ingelheim
Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncologyFurther data read-outs expected in 2024 in oncology, mental health, and pulmonary fibrosisStrong first half net sales...
Aerial view
Boehringer Ingelheim produces its own green energy
July 08, 2024 13:15 ET | Boehringer Ingelheim
German Vice Chancellor and Federal Minister of Economics Robert Habeck inaugurates new biomass power plantIngelheim site can cover 95% of its energy needs from renewable sourcesNew power plant helps...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024 04:30 ET | Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
May 28, 2024 07:00 ET | Boehringer Ingelheim
  International analysis of mental health provision in eight G20 countries reveals stigma, a shortage of mental health professionals and inconsistent availability and quality of care are creating...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
May 06, 2024 05:00 ET | Boehringer Ingelheim
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic...
Poultry image
Less than half of veterinary professionals feel their profession is appreciated
April 25, 2024 03:00 ET | Boehringer Ingelheim
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated. Veterinary associations and...
boehringer_biopharmaceutical production_Biberach resized
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 16, 2024 04:35 ET | Boehringer Ingelheim
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
SPEVIGO® approved for expanded indications in China and the US
March 19, 2024 07:00 ET | Boehringer Ingelheim
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue1,2,3,4In China,...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024 02:05 ET | Boehringer Ingelheim
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of...